Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Santa Clara, CA
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Baltimore, MD
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
New York, NY
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Ashville, NC
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Portland, OR
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Warwick, RI
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Dallas, TX
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated:  3/15/2011
Clinical Research Facility
mi
from
Norfolk, VA
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols.
An Open-label Study of the Safety of Pegasys Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Studies
Status: Enrolling
Updated: 3/15/2011
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Adolescents' Response to Hepatitis B Vaccine Booster Dose
Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood
Status: Enrolling
Updated:  4/22/2011
Texas Children's Hospital
mi
from
Houston, TX
Adolescents' Response to Hepatitis B Vaccine Booster Dose
Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood
Status: Enrolling
Updated: 4/22/2011
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Adolescents' Response to Hepatitis B Vaccine Booster Dose
Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood
Status: Enrolling
Updated:  4/22/2011
Texas Childrens Pediatric Associates
mi
from
Houston, TX
Adolescents' Response to Hepatitis B Vaccine Booster Dose
Project to Evaluate Hepatitis B Vaccine-induced Immunity Among US-born Adolescents Who Received Hepatitis B Primary Vaccination Series During Early Childhood
Status: Enrolling
Updated: 4/22/2011
Texas Childrens Pediatric Associates
mi
from
Houston, TX
Click here to add this to my saved trials
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment
Status: Enrolling
Updated:  6/22/2011
Johns Hopkins Drug Development Unit
mi
from
Baltimore, MD
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment
Status: Enrolling
Updated: 6/22/2011
Johns Hopkins Drug Development Unit
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated:  7/19/2011
Daytop Village, Bronx Outreach Center
mi
from
Bronx, NY
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated: 7/19/2011
Daytop Village, Bronx Outreach Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated:  7/19/2011
Daytop Village, Brooklyn Outreach Center
mi
from
Brooklyn, NY
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated: 7/19/2011
Daytop Village, Brooklyn Outreach Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated:  7/19/2011
Daytop Village, Queens Outreach Center
mi
from
Jamaica, NY
Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention
Comparative Effectiveness of Web-based vs. Traditional Adolescent HIV Prevention
Status: Enrolling
Updated: 7/19/2011
Daytop Village, Queens Outreach Center
mi
from
Jamaica, NY
Click here to add this to my saved trials
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin
Status: Archived
Updated:  7/19/2011
Clinical Research Facility
mi
from
Decatur, GA
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
Global Observational Cohort Study on the Prediction of Unwanted Adverse Effects in Individuals Infected With Chronic Hepatitis C Receiving a Long Acting Interferon Plus Ribavirin
Status: Archived
Updated: 7/19/2011
Clinical Research Facility
mi
from
Decatur, GA
Increasing Viral Testing in the Emergency Department
Phase 2/3 Clinical Trial of the Effect of a Brief Intervention on Uptake of Rapid Testing for HIV and Hepatitis C Among Emergency Department Patients
Status: Enrolling
Updated:  8/16/2011
Rhode Island Hospital Emergency Department
mi
from
Providence, RI
Increasing Viral Testing in the Emergency Department
Phase 2/3 Clinical Trial of the Effect of a Brief Intervention on Uptake of Rapid Testing for HIV and Hepatitis C Among Emergency Department Patients
Status: Enrolling
Updated: 8/16/2011
Rhode Island Hospital Emergency Department
mi
from
Providence, RI
Click here to add this to my saved trials
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/HCV Negative Volunteers
A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/HCV Negative Volunteers
Status: Enrolling
Updated:  8/31/2011
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/HCV Negative Volunteers
A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/HCV Negative Volunteers
Status: Enrolling
Updated: 8/31/2011
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
Post Transplant Course of Hepatitis C Patients After Living Donor Liver Transplant in Association With Interleukin 28 B
Status: Enrolling
Updated:  9/2/2011
Henry Ford Hospital
mi
from
Detroit, MI
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
Post Transplant Course of Hepatitis C Patients After Living Donor Liver Transplant in Association With Interleukin 28 B
Status: Enrolling
Updated: 9/2/2011
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Q-Trial in Patients With Hepatitis C
A Phase 1 Study of Quercetin in Patients With Hepatitis C
Status: Enrolling
Updated:  9/20/2011
UCLA Jonsson Comprehensive Cancer Center. Factor Building
mi
from
los Angeles, CA
Q-Trial in Patients With Hepatitis C
A Phase 1 Study of Quercetin in Patients With Hepatitis C
Status: Enrolling
Updated: 9/20/2011
UCLA Jonsson Comprehensive Cancer Center. Factor Building
mi
from
los Angeles, CA
Click here to add this to my saved trials
Directly Observed Hepatitis C Treatment in Methadone Clinics
Directly Observed Hepatitis C Treatment in Methadone Clinics
Status: Enrolling
Updated:  9/27/2011
Albert Einstein College of Medicine - Division of Substance Abuse
mi
from
Bronx, NY
Directly Observed Hepatitis C Treatment in Methadone Clinics
Directly Observed Hepatitis C Treatment in Methadone Clinics
Status: Enrolling
Updated: 9/27/2011
Albert Einstein College of Medicine - Division of Substance Abuse
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Aurora, CO
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Aurora, CO
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Decatur, GA
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Decatur, GA
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Dallas, TX
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Dallas, TX
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated:  2/8/2012
Clinical Research Facility
mi
from
Norfolk, VA
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection
Status: Archived
Updated: 2/8/2012
Clinical Research Facility
mi
from
Norfolk, VA
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
South Denver Gastroenterology
mi
from
Englewood, CO
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
South Denver Gastroenterology
mi
from
Englewood, CO
Click here to add this to my saved trials
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
Digestive Medicine Associates
mi
from
Hialeah, FL
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
Digestive Medicine Associates
mi
from
Hialeah, FL
Click here to add this to my saved trials
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
Florida Center for Gastroenterology
mi
from
Largo, FL
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
Florida Center for Gastroenterology
mi
from
Largo, FL
Click here to add this to my saved trials
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
Marwan Iskandarani, MD
mi
from
North Miami Beach, FL
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
Marwan Iskandarani, MD
mi
from
North Miami Beach, FL
Click here to add this to my saved trials
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
Saint Luke's Hospital
mi
from
Chesterfield, MO
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
Saint Luke's Hospital
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
North Shore University Hospital
mi
from
Manhasset, NY
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated:  2/13/2012
Metropolitan Research
mi
from
Fairfax, VA
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program
Status: Enrolling
Updated: 2/13/2012
Metropolitan Research
mi
from
Fairfax, VA
Click here to add this to my saved trials
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Status: Enrolling
Updated:  2/23/2012
Univ of North Carolina
mi
from
Chapel Hill, NC
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling
Status: Enrolling
Updated: 2/23/2012
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
Status: Enrolling
Updated:  3/21/2012
VCU Medical Center
mi
from
Richmond, VA
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo-Controlled Dosing, Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis
Status: Enrolling
Updated: 3/21/2012
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection
Status: Enrolling
Updated:  3/22/2012
Clinical Research Facility
mi
from
San Francisco, CA
A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Antiviral Efficacy of PPI-668 in Healthy Volunteers and Patients With HCV Genotype-1 Infection
Status: Enrolling
Updated: 3/22/2012
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/2/2012
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/2/2012
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/2/2012
Avail Clinical Research
mi
from
DeLand, FL
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/2/2012
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/2/2012
Orlando Clinical Research Center
mi
from
Orlando, FL
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/2/2012
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/2/2012
Kansas City Gastroenterology & Hepatology
mi
from
Kansas City, MO
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/2/2012
Kansas City Gastroenterology & Hepatology
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/2/2012
Comprehensive Clinical Research
mi
from
Berlin, NJ
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/2/2012
Comprehensive Clinical Research
mi
from
Berlin, NJ
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/2/2012
CRI Worldwide, LLC
mi
from
Willingboro, NJ
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/2/2012
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated:  5/2/2012
Clinilabs Inc.
mi
from
New York, NY
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection
Status: Enrolling
Updated: 5/2/2012
Clinilabs Inc.
mi
from
New York, NY
Click here to add this to my saved trials